Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Nihon Pharmaceutical Co.Ltd |
|---|---|
| Manufacturer | Nihon Pharmaceutical Co.Ltd. |
| Prescription required | Yes |
NKS-1 combination OD tablet T25,25mg x 56 (Tegafur/Gimeracil/Oteracil Potassium)
Tegafur/Gimeracil/Oteracil Potassium
Description
NKS-1 combination OD tablet T25,25mg x 56(/ /) (Tegafur/Gimeracil/Oteracil Potassium) is a medicine catalog record in the MediPriceHub database. Active ingredient: Tegafur/Gimeracil/Oteracil Potassium. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Nihon Pharmaceutical Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Pack information: 25 / 7.25 / 24.5 / 56. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Amoxicillin and Clavulanate Potassium is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species.How to Use
Use Tegafur/Gimeracil/Oteracil Potassium under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Tegafur/Gimeracil/Oteracil Potassium. Pack size: 25 / 7.25 / 24.5 / 56. Pack unit: box. Manufacturer: Nihon Pharmaceutical Co.Ltd.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Bile duct cancer, bile duct cancer drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.This information is for reference only. Consult a qualified healthcare professional before using any medicine.